Targeting ST8SIA6-AS1 counteracts KRAS<sup>G12C</sup> inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling.

Authors:
Wang Y; Yao M; Li C; Yang K; Qin X and 5 more

Journal:
Exp Hematol Oncol

Publication Year: 2023

DOI:
10.1186/s40164-023-00466-3

PMCID:
PMC10724920

PMID:
38104151

Journal Information

Full Title: Exp Hematol Oncol

Abbreviation: Exp Hematol Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateAll in vivo experiments were carried out according to the institutional ethical guidelines on animal care and were approved by the Institute of Animal Care and Use Committee at the Shanghai Institute of Materia Medica. Consent for publicationAll authors have read the manuscript and provided their consent for the submission. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by the grants from the Lingang Laboratory (LG202101-01-06) and the Natural Science Foundation of Shanghai (19ZR1467700), and ShanghaiTech University and the Shanghai Municipal Government."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025